Seguir
samuel denmeade
samuel denmeade
Afiliación desconocida
Dirección de correo verificada de jhmi.edu
Título
Citado por
Citado por
Año
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
27862014
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ...
JAMA oncology 6 (5), 650-659, 2020
7892020
A history of prostate cancer treatment
SR Denmeade, JT Isaacs
Nature Reviews Cancer 2 (5), 389-396, 2002
7702002
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
6732015
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
SR Denmeade, XS Lin, JT Isaacs
The prostate 28 (4), 251-265, 1996
5941996
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ...
Journal of Clinical Oncology 28 (9), 1496, 2010
5362010
Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with …
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ...
Journal of Clinical Oncology 35 (19), 2149, 2017
4292017
Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death
R Na, SL Zheng, M Han, H Yu, D Jiang, S Shah, CM Ewing, L Zhang, ...
European urology 71 (5), 740-747, 2017
3572017
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
SR Denmeade, CM Jakobsen, S Janssen, SR Khan, ES Garrett, H Lilja, ...
Journal of the National Cancer Institute 95 (13), 990-1000, 2003
3532003
The SERCA pump as a therapeutic target: making a “smart bomb” for prostate cancer
SR Denmeade, JT Isaacs
Cancer biology & therapy 4 (1), 21-29, 2005
2752005
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
SR Denmeade, W Lou, J Lövgren, J Malm, H Lilja, JT Isaacs
Cancer research 57 (21), 4924-4930, 1997
2711997
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
IB Joseph, JB Nelson, SR Denmeade, JT Isaacs
Clinical cancer research: an official journal of the American Association …, 1997
2701997
Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy
WN Brennen, JT Isaacs, SR Denmeade
Molecular cancer therapeutics 11 (2), 257-266, 2012
2592012
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study
MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ...
Science translational medicine 7 (269), 269ra2-269ra2, 2015
2572015
Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy
SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ...
Science translational medicine 4 (140), 140ra86-140ra86, 2012
2492012
Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise
TEG Krueger, DLJ Thorek, SR Denmeade, JT Isaacs, WN Brennen
Stem cells translational medicine 7 (9), 651-663, 2018
2272018
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen
SR Denmeade, A Nagy, J Gao, H Lilja, AV Schally, JT Isaacs
Cancer research 58 (12), 2537-2540, 1998
2191998
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug
WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade
Journal of the National Cancer Institute 104 (17), 1320-1334, 2012
1992012
Knockin of mutant PIK3CA activates multiple oncogenic pathways
JP Gustin, B Karakas, MB Weiss, AM Abukhdeir, J Lauring, JP Garay, ...
Proceedings of the National Academy of Sciences 106 (8), 2835-2840, 2009
1822009
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
BA Teply, H Wang, B Luber, R Sullivan, I Rifkind, A Bruns, A Spitz, ...
The Lancet Oncology 19 (1), 76-86, 2018
1782018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20